From the results of COVID-19 clinical research, we can find CPMs can regulate the proportion of lymphocyte and leukocyte, significantly reduce the level of inflammation factors such as CRP, D-dimer, PCT, IL6, IL10, IL17, TNF-α, and IFN-γ, and increase the level of IL4 (Chen et al., 2020c; Qin et al., 2020). This evidence concerns the gene IL17A and COVID-19.